Tryton Medical has announced that the first US commercial case using the Tryton Side branch stent to treat a coronary bifurcation lesion involving a large side branch (appropriate for a ≥2.5mm stent) was completed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City, USA.
A new meta-analysis presented this week at the American College of Cardiology 66th Scientific Sessions (ACC; 17-19 March, Washington DC, UK) offers support to the ability of RenalGuard therapy to significantly reduce the incidence of acute kidney injury associated with cardiovascular interventional procedures compared to other methods of urine volume expansion.
The FDA has approved Medtronic’s CoreValve Evolut Pro transcatheter aortic valve implantation (TAVI) device. This approval follows data for the device that were presented at the 2017 scientific sessions of the American College of Cardiology (ACC; 17–19 March, Washington, DC, USA); these 30-day clinical data, a press release reports, show that CoreValve Evolut Pro is associated with high survival, low rates of stroke, minimal paravalvular leak and excellent haemodynamics.
Cardiologists can now access the advanced ultrasound imaging technology needed for fast and confident diagnoses with Toshiba Medical’s Aplio i900. The newly US Food and Drug Administration (FDA)-cleared system is the latest addition to the premium Aplio i-series ultrasound platform.
Siemens Healthineers and HeartFlow are to collaborate on joint-solution computed tomography (CT) scanners, intended to provide a comprehensive, noninvasive solution to support the diagnosis and management of patients with suspected coronary artery disease.
Amgen has announced detailed results from the evolocumab (Repatha) cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the evolocumab cardiovascular outcomes study, FOURIER.
Unfors RaySafe has introduced the RaySafe i3, to its suite of real-time dosimetry products, at the European Society of Radiology in Vienna.
The Medicines Company and Alnylam Pharmaceuticals have announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment of hypercholesterolemia.
Of 84 older patients undergoing transcatheter aortic valve implantationt (TAVI), nearly a quarter developed new microbleeds in the brain after their procedure, according to results of a single-centre study presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC; 17-19 March, Washington, DC, USA).
The 12-month results of Biotronik’s BIOFLOW-IV multicentre clinical study have been presented at the 2-17 Japan Circulation Society congress (JCS; 17-19 March, Kanazawa, Japan). The BIOFLOW-IV study is a prospective multi-centre, randomised controlled trial with a five-year follow-up. The positive results of this study support the submission for Japanese market approval.
Two US Food and Drug Administration-cleared medical devices designed to remove potential vessel-blocking debris particles from the bloodstream during aortic valve replacement—EmbolX (Edwards LifeSciences) and CardioGard (CardioGard Medical)—did not significantly reduce overall number of brain infarcts over standard surgical procedure, according to a study presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC; 17-19 March, Washington, DC, USA).
New recommendations have been published by the American Heart Association and the American College of Cardiology, aiming to clarify which patients who have malfunctioning heart valves may benefit from artificial valves replaced through a minimally invasive procedure and the need for antibiotics for some patients prior to a dental procedure, as well as expand the age range for choosing tissue valve replacement.
Writing in The New England Journal of Medicine, Deepak L Bhatt (Brigham and Women’s Hospital and Vascular Center and Harvard Medical School, Boston, USA) suggests that instantaneous wave-free ratio (iFR; Philips Volcano) may be the new standard of assessing coronary lesions after two studies indicated that iFR was non-inferior to fractional flow reserve (FFR) with respect to the one-year rate of major adverse cardiac events (MACE). Both studies also found FFR was associated with significantly more procedural-related adverse events than was iFR.
The Tsimane people—a forager-horticulturalist population of the Bolivian Amazon—have the lowest reported levels of vascular ageing for any population, with coronary atherosclerosis being five times less common than in the USA, according to a study published in the Lancet and being presented at the American College of Cardiology 66th Annual Scientific Sessions (ACC; 17-19 March, Washington, DC, USA).
Acarix has announced the results from a new multicentre trial of its handheld CADScor system for non-invasive, non-radiation acoustic detection of coronary artery disease. The results were presented at the 2017 scientific sessions of the American College of Cardiology (ACC; 17-19 March, Washington, DC) and showed that the handheld CADScor system can rule out coronary artery disease with 97% negative predictive value.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos